NUWE Nuwellis, Inc.

Executive Summary

Nuwellis, Inc. filed Amendment No. 2 to its S-1 registration statement for a best-efforts standby equity offering of up to 6,578,948 shares of common stock (or pre-funded warrants in lieu thereof), together with Series C and Series D common warrants, at an assumed combined price of $0.76 per share and accompanying warrants. The offering has no minimum and terminates June 30, 2026; net proceeds are estimated at ~$4.4M if fully subscribed. The company has a $1M market cap, a history of operating losses (net loss of $17.5M in FY2025, accumulated deficit of $316.3M), and only enough cash to fund operations through Q2 2026, making this a dilutive emergency capital raise.

Actionable Insight

Key Facts

• Best-efforts offering of up to 6,578,948 shares of common stock or pre-funded warrants, with Series C and Series D common warrants, at an assumed combined price of $0.76 per share and accompanying warrants.
• No minimum offering amount; offering terminates June 30, 2026.
• Estimated net proceeds of ~$4.4M if fully subscribed; proceeds used for working capital and general corporate purposes.
• Company had $2.083M in cash as of March 31, 2026, with only enough cash to fund operations through Q2 2026.
• Net loss of $17.5M for FY2025; accumulated deficit of $316.3M as of December 31, 2025.
• Concurrent private transaction to reduce exercise price of up to 3,284,788 outstanding warrants to the public offering price.
• Common warrants exercisable only after stockholder approval and reverse stock split; Series D warrants have zero-cash exercise option providing no additional proceeds.
• Market cap of $1M; stock price $0.76 as of May 27, 2026.
• Two material weaknesses in internal control over financial reporting identified.
• Nasdaq delisting risk: company received deficiency notice for bid price non-compliance in June 2025, subsequently resolved via reverse stock split.

Financial Impact

Maximum gross proceeds of ~$5.0M from the offering; net proceeds ~$4.4M after fees and expenses. Additional ~$5.0M possible if common warrants exercised for cash, but Series D warrants provide zero cash exercise. Company had $2.083M cash as of March 31, 2026, with net loss of $17.5M in FY2025.

Risk Factors

• Offering has no minimum; may raise substantially less than $4.4M, insufficient to fund operations beyond Q2 2026.
• Massive dilution: up to 6.6M shares + 26.3M warrant shares vs. 2.6M shares outstanding.
• Series D warrants provide zero cash exercise, yielding no additional proceeds.
• Common warrants require stockholder approval and reverse stock split to become exercisable; may never be exercisable.
• Company has only $2.083M cash and $17.5M annual net loss; going-concern risk if offering undersubscribed.
• Nasdaq delisting risk remains; stock price at $0.76 near $1.00 minimum bid requirement.
• Two material weaknesses in internal controls could lead to financial reporting errors.
• Litigation risk from E.F. Hutton lawsuit (settled April 2026) and potential future lawsuits.

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status